Acalabrutinib Monotherapy in Patients With Ibrutinib Intolerance: Results From the Phase 1/2 ACE-CL-001 Clinical Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 16
页数：3
相关论文
共 50 条
  • [21] Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
    Shadman, Mazyar
    Sharman, Jeff P.
    Levy, Moshe Y.
    Misleh, Jamal
    Zafar, Syed F.
    Freeman, Benjamin B.
    Burke, John M.
    Cultrera, Jennifer L.
    Yimer, Habte A.
    Chen, Dih-Yih
    Zhang, Xiaoping
    Cohen, Aileen
    Ro, Sunhee
    Huang, Jane
    Flinn, Ian W.
    BLOOD, 2020, 136
  • [22] Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
    Rogers, Kerry Anne
    Thompson, Philip A.
    Allan, John Nathan
    Coleman, Morton
    Sharman, Jeff Porter
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng Seok
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up
    Byrd, John C.
    Woyach, Jennifer A.
    Furman, Richard R.
    Martin, Peter
    O'Brien, Susan
    Brown, Jennifer R.
    Stephens, Deborah M.
    Barrientos, Jacqueline C.
    Patten, Piers Em
    Munir, Talha
    Patel, Krish
    Butturini, Anna
    de Borja, Marianne
    Wang, Min Hui
    Jain, Nitin
    Wierda, William G.
    BLOOD, 2022, 140 : 9865 - 9867
  • [24] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
  • [25] Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study
    Xu, Linlin
    Shadman, Mazyar
    Flinn, Ian W.
    Levy, Moshe
    Porter, Ryan
    Burke, John M.
    Zafar, Syed F.
    Cultrera, Jennifer L.
    Misleh, Jamal
    Kingsley, Edwin C.
    Yimer, Habte A.
    Freeman, Benjamin B.
    Chaudhry, Arvind
    Tumula, Praveen K.
    Gandhi, Mitul
    Crescenzo, Rocco J.
    By, Kunthel
    Cohen, Aileen Cleary
    Idoine, Adam
    Manda, Sudhir
    Sharman, Jeff P.
    BLOOD, 2023, 142
  • [26] Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
    Mar, Nataliya
    Zakharia, Yousef
    Falcon, Alejandro
    Morales-Barrera, Rafael
    Mellado, Begona
    Duran, Ignacio
    Oh, Do-Youn
    Williamson, Stephen K.
    Gajate, Pablo
    Arkenau, Hendrik-Tobias
    Jones, Robert J.
    Teo, Min Yuen
    Turan, Tolga
    McLaughlin, Robert T.
    Peltier, Hillary M.
    Chong, Elizabeth
    Atluri, Harisha
    Dean, James P.
    Castellano, Daniel
    CANCERS, 2023, 15 (11)
  • [27] A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Lupo, Letizia
    Finazzi, Maria Chiara
    Tozzi, Lorenzo
    Biamonte, Flavia
    Masciulli, Arianna
    Susini, Maria Chiara
    Pancrazzi, Alessandro
    Finazzi, Guido
    Paratore, Simona
    Marchioli, Roberto
    Bosi, Alberto
    Barbui, Tiziano
    Rambaldi, Alessandro
    Barosi, Giovanni
    BLOOD, 2010, 116 (21) : 143 - 143
  • [28] Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study
    Fowler, Nathan
    Nastoupil, Loretta
    de Vos, Sven
    Knapp, Mark
    Flinn, Ian W.
    Chen, Robert
    Advani, Ranjana H.
    Bhatia, Sumeet
    Martin, Peter
    Mena, Raul
    Suzuki, Samuel
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Palomba, M. Lia
    BLOOD, 2015, 126 (23)
  • [29] Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)
    Strati, Paolo
    Agajanian, Richy
    Lossos, Izidore S.
    Coleman, Morton
    Kridel, Robert
    Wood, Andrew
    Lesley, Robin
    Wun, Chuan-Chuan
    Stephens, Deborah M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (03) : 887 - 898
  • [30] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
    Furman, Richard R.
    Wierda, William G.
    Schuh, Anna
    Devereux, Stephen
    Chaves, Jorge M.
    Brown, Jennifer R.
    Hillmen, Peter
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline C.
    Pagel, John M.
    Woyach, Jennifer
    Burke, Kathleen
    Covey, Todd
    Gulrajani, Michael
    Hamdy, Ahmed
    Izumi, Raquel
    Frigault, Melanie M.
    Patel, Priti
    Rothbaum, Wayne
    Wang, Min Hui
    O'Brien, Susan M.
    Byrd, John C.
    BLOOD, 2019, 134
12345